Clinical Trial Update: Anti-PD-L1/TGF-beta Trap (M7824) Alone and in Combination With TriAd Vaccine and N-803 for Resectable Head and Neck Squamous Cell Carcinoma Not Associated With Human Papillomavirus Infection [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial of M7824 (bintrafusp alfa) alone and in combination with TriAd vaccine and N-803 for resectable HPV-unrelated head and neck squamous cell carcin…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Head and Neck Squamous Cell Carcinoma

Drugs mentioned

• M7824 (bintrafusp alfa) (bintrafusp alfa)
• N-803
• TriAd vaccine

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Head and Neck Cancer, Head and Neck Neoplasms | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2023-08-08